Annexon Biosciences
Public / Post-IPOTherapeutic medicines targeting classical complement-mediated neurodegeneration and autoimmune diseases
BiotechnologyTotal Raised: $50M👥 101-250 Employees📍 Brisbane, USA
About Annexon Biosciences
Annexon Biosciences is a clinical-stage biopharmaceutical company pioneering novel therapies that inhibit C1q, the initiating molecule of the classical complement pathway. Their lead antibody candidates target Guillain-Barré syndrome, Huntington's disease, and geographic atrophy.
Founders & Leadership
Douglas LevinsonCo-Founder & CEO
Ben BarresCo-Founder
Investors & Backers
Funding History
1 roundSimilar Companies in Biotechnology
Explore verified active tech startups operating in the Biotechnology space.